fingolimod hydrochloride has been researched along with carboplatin in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 12,895 | 4,001 | 5,244 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, RD; Arend, RC; Fehling, SC; Gamblin, TL; Katre, AA; Kreitzburg, KM; Landen, CN; Oliver, PG; van Waardenburg, RCAM; Vance, RB; Yoon, KJ | 1 |
1 other study(ies) available for fingolimod hydrochloride and carboplatin
| Article | Year |
|---|---|
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Fingolimod Hydrochloride; Humans; Mice; Ovarian Neoplasms; Tamoxifen; Xenograft Model Antitumor Assays | 2018 |